AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL342.94-0.52 (-0.15%) ▼|ABBV282.68-2.74 (-0.96%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.93+7.25 (+3.16%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.03-2.24 (-1.21%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.41+2.82 (+0.90%) ▲|BA191.42+1.21 (+0.64%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.60-9.78 (-0.86%) ▼|BMY58.83-0.92 (-1.54%) ▼|BNY142.44-0.86 (-0.60%) ▼|BRK-B532.23+0.21 (+0.04%) ▲|C121.69-2.57 (-2.07%) ▼|CAT725.79-4.97 (-0.68%) ▼|CL93.39-0.72 (-0.77%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.83-1.91 (-0.95%) ▼|COP145.24-1.27 (-0.87%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.45+1.75 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.35%) ▲|CVX224.37-0.62 (-0.28%) ▼|DE627.00-14.86 (-2.32%) ▼|DHR224.43-4.61 (-2.01%) ▼|DIS109.59-1.00 (-0.90%) ▼|DUK119.27-2.20 (-1.81%) ▼|EMR160.54-0.93 (-0.58%) ▼|FDX293.78+0.23 (+0.08%) ▲|GD341.43-2.80 (-0.81%) ▼|GE311.28-2.55 (-0.81%) ▼|GEV908.44-12.76 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.75-1.21 (-1.44%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.78-5.48 (-0.62%) ▼|HD309.88+0.25 (+0.08%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.39+4.25 (+1.83%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.79-1.77 (-0.69%) ▼|JPM333.53-6.19 (-1.82%) ▼|KO93.42-0.48 (-0.51%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.34-16.69 (-1.33%) ▼|LMT548.23-3.86 (-0.70%) ▼|LOW195.92-1.46 (-0.74%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.40-1.02 (-0.17%) ▼|MCD242.67-0.30 (-0.12%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.77-1.98 (-2.09%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.01-2.74 (-1.66%) ▼|MO74.09-1.02 (-1.36%) ▼|MRK143.63-2.32 (-1.59%) ▼|MS178.47-2.10 (-1.16%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.17-1.63 (-2.04%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.21+0.08 (+0.22%) ▲|NOW145.36+3.39 (+2.39%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.59+1.36 (+1.06%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.44-0.14 (-0.47%) ▼|PG157.69-1.66 (-1.04%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM201.05-4.15 (-2.02%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.38-10.62 (-1.54%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
17.7 C
New York
Monday, October 19, 2026

Tag: novel

newssourceFORcompanycontentinformation1releasesmarket

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide

MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models0602K shows profound beneficial transformation of...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCLACEL PHARMACEUTICALS ANNOUNCES $3 MILLION PRIVATE PLACEMENT OFFERING OF CONVERTIBLE PREFERRED STOCK

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Virtual webinar on June 23, 2025 at 8:00 am ET 
Virtual webinar on June 23, 2025 at 8:00 am ET

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

PharmAla Files Preliminary Base Shelf Prospectus

Pharmala files short form prospectus

Long Island University to Host Summer Creative Writing Workshop with Acclaimed Author Zoraida Córdova at LIU Brooklyn

Daylong Literary Events to Follow Featuring 25 Local Authors and Community Events BROOKLYN, N.Y., June 20, 2025 /PRNewswire/ -- Long Island University announces its upcoming Creative...

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO,...

Yale School of Medicine Launches Yale Biomedical Imaging Institute

NEW HAVEN, Conn., June 20, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a...

Natural Carotenoids Market Poised to Reach $3.3 Billion by 2035, Growing at a CAGR of 8.7% from 2025–Exclusive Report by Meticulous Research®

Market valued at $1.35 billion in 2024 set to grow at 8.7% CAGR through 2035, driven by surging demand for natural food colors and...

Natural Carotenoids Market Poised to Reach $3.3 Billion by 2035, Growing at a CAGR of 8.7% from 2025–Exclusive Report by Meticulous Research®

Market valued at $1.35 billion in 2024 set to grow at 8.7% CAGR through 2035, driven by surging demand for natural food colors and...

Yale School of Medicine Launches Yale Biomedical Imaging Institute

NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a cross-disciplinary hub that...

Black Soldier Fly (BSF) Market to Reach $5.60 Billion by 2035, Growing at a CAGR of 29% from 2025–Exclusive Report by Meticulous Research®

Market Growth Driven by Sustainable Protein Demand, Waste Management Solutions, Aquaculture Expansion, and Regulatory Support for Insect-Based Products REDDING, Calif., June 20, 2025 /PRNewswire/ --...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNovel

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers